(Q35954629)

English

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Désirée van der Heijde

8

object named as

Désirée van der Heijde

0 references

author name string

Norihiro Nishimoto

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jun Hashimoto

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Nobuyuki Miyasaka

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Kazuhiko Yamamoto

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Shinichi Kawai

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tsutomu Takeuchi

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Norikazu Murata

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Tadamitsu Kishimoto

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

7 May 2007

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

66

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1162-1167

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Interleukin-6 in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Interleukin-6 in biology and medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Rheumatoid arthritis. Pathophysiology and implications for therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

2 October 2017

Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

11 July 2018

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955155

24 September 2018

How to read radiographs according to the Sharp/van der Heijde method

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17485422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2006.068064

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

release_dhcg2r7eendptpfcuc5hgej2dy

1 reference

https://api.fatcat.wiki/v0/release/dhcg2r7eendptpfcuc5hgej2dy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35954629&oldid=1962349541"